论文部分内容阅读
目的探讨活化白细胞粘附分子(ALCAM)在卵巢浆液性肿瘤中的表达及其意义。方法使用免疫组化法检测ALCAM在卵巢良性、交界性及恶性浆液性性肿瘤病灶中的表达。使用Elisa检测卵巢肿瘤患者术前血清中ALCAM浓度。结果卵巢良性、交界及恶性浆液性肿瘤患者血清均可检测到ALCAM,三组间浓度无统计学差异。ALCAM在卵巢良性、交界性、恶性肿瘤中的阳性表达率分别为:31.8%、28.5%及62.2%。良性与恶性肿瘤组间ALCAM蛋白表达率差异有统计学意义(P=0.001)。卵巢恶性肿瘤组织中ALCAM蛋白的表达与手术分期、是否有淋巴结转移及预后有相关性。ALCAM阳性组卵巢恶性肿瘤患者5年生存率为23.5%,而ALCAM阴性组为50.0%,二者之间差异有统计学意义(P=0.02)。结论卵巢恶性肿瘤组织中ALCAM表达增强为卵巢恶性肿瘤不良预后的指标。
Objective To investigate the expression and significance of activated leukocyte adhesion molecule (ALCAM) in ovarian serous tumors. Methods The expression of ALCAM in benign, borderline and malignant serous tumors of ovary was detected by immunohistochemistry. Elisa was used to detect preoperative serum ALCAM concentrations in patients with ovarian tumors. Results ALCAM was detected in the sera of benign ovarian, borderline and malignant serous tumors, with no significant difference among the three groups. The positive rates of ALCAM in benign ovarian, borderline and malignant tumors were 31.8%, 28.5% and 62.2% respectively. There was significant difference in ALCAM protein expression between benign and malignant tumors (P = 0.001). The expression of ALCAM protein in ovarian cancer tissues is correlated with the staging, lymph node metastasis and prognosis. The 5-year survival rate of patients with ALCAM positive ovarian cancer was 23.5%, while the ALCAM negative group was 50.0%, the difference was statistically significant (P = 0.02). Conclusion The increased expression of ALCAM in ovarian malignant tumors is an indicator of poor prognosis of ovarian cancer.